{"url_path":"/sec/engnw/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270384-index.html","accession_number":"0001193125-26-270384","cik":"0001980845","ticker":"ENGN","issuer_name":"enGene Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270384-index.html","primary_entity_key":"0001980845","primary_entity_name":"enGene Therapeutics Inc."},"word_count":123,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 15, 2026, the Company issued a press release announcing its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates related to the strategic restructuring. The full text of the press release is set forth in Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing."}